TY - JOUR A1 - Pereira, P.M.R. A1 - Korsak, B. A1 - Sarmento, B. A1 - Schneider, Rudolf A1 - Fernandes, R. A1 - Tomé, J.P.C. T1 - Antibodies armed with photosensitizers: from chemical synthesis to photobiological applications N2 - Targeting photosensitizers to cancer cells by conjugating them with specific antibodies, able to recognize and bind to tumor-associated antigens, is today one of the most attractive strategies in photodynamic therapy (PDT). This comprehensive review updates on chemical routes available for the preparation of photo-immunoconjugates (PICs), which show dual chemical and biological functionalities: photo-properties of the photosensitizer and the immunoreactivity of the antibody. Moreover, photobiological results obtained with such photo-immunoconjugates using in vitro and in vivo cancer models are also discussed. KW - Therapeutische Antikörper KW - Krebstherapie KW - Photodynamische Therapie KW - Konjugate KW - Porphyrine KW - Phthalocyanine KW - Chlorine KW - Kopplungsmethoden PY - 2015 DO - https://doi.org/10.1039/c4ob02334j SN - 1477-0520 SN - 1477-0539 VL - 13 IS - 9 SP - 2518 EP - 2529 PB - RSC CY - Cambridge AN - OPUS4-32734 LA - eng AD - Bundesanstalt fuer Materialforschung und -pruefung (BAM), Berlin, Germany ER - TY - JOUR A1 - Pereira, P.M.R. A1 - Carvalho, José Joao A1 - Silva, S. A1 - Cavaleiro, J.A.S. A1 - Schneider, Rudolf A1 - Fernandes, R. A1 - Tomé, J.P.C. T1 - Porphyrin conjugated with serum albumins and monoclonal antibodies boosts efficiency in targeted destruction of human bladder cancer cells N2 - The synthesis of a novel PS conjugated with bovine and human serum albumin (BSA and HSA) and a monoclonal antibody anti-CD104 is reported, as well as their biological potential against the human bladder cancer cell line UM-UC-3. No photodynamic effect was detected when the non-conjugated porphyrin was used. Yet, when it was coupled covalently with the mAb anti-CD104, BSA and HSA, the resulting photosensitizer conjugates demonstrated high efficacy in destroying the cancer cells, the mAb anti-CD104 efficacy overruling the albumins. KW - Rinderserumalbumin KW - BSA KW - Monoklonale Antikörper KW - Blasenkrebs KW - Konjugate KW - Conjugates KW - Therapeutische Antikörper KW - CD104 PY - 2014 DO - https://doi.org/10.1039/c3ob42082e SN - 1477-0520 SN - 1477-0539 VL - 12 IS - 11 SP - 1804 EP - 1811 PB - RSC CY - Cambridge AN - OPUS4-30451 LA - eng AD - Bundesanstalt fuer Materialforschung und -pruefung (BAM), Berlin, Germany ER -